Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Feasibility of Outpatient Consolidation Chemotherapy and Toxicity in Elderly Patients with AML.

Richard Ward, BSc, MRCP, FRCPath, Vikas Gupta, MD, Mark D. Minden, MD, PhD, Aaron D. Schimmer, MD, PhD, Karen WL Yee, MD, Andre Schuh, MD, Wei Xu, PhD, Joseph Brandwein, MD

Blood (2009) 114 (22): 1036.

https://doi.org/10.1182/blood.V114.22.1036.1036

Published: 2009

Journal Articles

Lack of Inhibition of AKT Predicts Clinical Resistance to Therapy with Imatinib + Reinduction Chemotherapy in Relapsed/Refractory c-Kit+ Acute Myeloid Leukemia.

Joseph Brandwein, MD, David Hedley, MD, Sue Chow, Aaron D. Schimmer, MD, PhD, Karen WL Yee, Andre Schuh, MD, Vikas Gupta, Mark D. Minden, MD, PhD

Blood (2009) 114 (22): 2073.

https://doi.org/10.1182/blood.V114.22.2073.2073

Published: 2009

Journal Articles

Low-Level FLT3-ITD Mutations Do Not Predict for Higher Relapse Rate in AML with Standard Risk Karyotpye.

Richard Ward, BSc, MRCP, FRCPath, Suzanne Kamel-Reid, PhD, FACMG, Wei Xu, PhD, Mark D. Minden, MD, PhD, Aaron D. Schimmer, MD, PhD, Karen WL Yee, MD, Andre Schuh, MD, Vikas Gupta, MD, Joseph Brandwein, MD

Blood (2009) 114 (22): 1591.

https://doi.org/10.1182/blood.V114.22.1591.1591

Published: 2009

Journal Articles

Treatment of Adult T-ALL with a Pediatric Asparaginase-Intensive Protocol Results in Survival Benefit When Compared to Other Adult Based Protocols

Murtadha K. Al-Khabori, BSc, MD, FRCPC, Mark Minden, Vikas Gupta, Aaron D. Schimmer, Andre C. Schuh, Karen WL Yee, Wei Xu, Joseph M. Brandwein

Blood (2008) 112 (11): 3956.

https://doi.org/10.1182/blood.V112.11.3956.3956

Published: 2008

Journal Articles

Outcome of Patients Age 60 and Over with Acute Lymphoblastic Leukemia (ALL) Treated with a Modified Pediatric Protocol

Susan Kao, MD, Wei Xu, PhD, Vikas Gupta, MD, MRCP, MRCPath, Mark Minden, Andre Schuh, MD, Aaron D. Schimmer, Karen WL Yee, Joseph Brandwein, MD, FRCPC

Blood (2008) 112 (11): 3962.

https://doi.org/10.1182/blood.V112.11.3962.3962

Published: 2008

Journal Articles

Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Wendy Stock, MD, Karen WL Yee, MD, Eunice S. Wang, MD, Sari Enschede, MD, Joyce Steinberg, MD, Rod Humerickhouse, MD, PhD, Qin Qin, PhD, Jiang Qian, PhD, Yi-Lin Chiu, PhD, Neeraj Gupta, PhD, Rajendra Pradhan, PhD

Blood (2008) 112 (11): 4008.

https://doi.org/10.1182/blood.V112.11.4008.4008

Published: 2008

NARROW

Feasibility of Outpatient Consolidation Chemotherapy and Toxicity in Elderly Patients with AML.

Lack of Inhibition of AKT Predicts Clinical Resistance to Therapy with Imatinib + Reinduction Chemotherapy in Relapsed/Refractory c-Kit+ Acute Myeloid Leukemia.

Low-Level FLT3-ITD Mutations Do Not Predict for Higher Relapse Rate in AML with Standard Risk Karyotpye.

Treatment of Adult T-ALL with a Pediatric Asparaginase-Intensive Protocol Results in Survival Benefit When Compared to Other Adult Based Protocols

Outcome of Patients Age 60 and Over with Acute Lymphoblastic Leukemia (ALL) Treated with a Modified Pediatric Protocol

Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

Feasibility of Outpatient Consolidation Chemotherapy and Toxicity in Elderly Patients with AML.

Lack of Inhibition of AKT Predicts Clinical Resistance to Therapy with Imatinib + Reinduction Chemotherapy in Relapsed/Refractory c-Kit+ Acute Myeloid Leukemia.

Low-Level FLT3-ITD Mutations Do Not Predict for Higher Relapse Rate in AML with Standard Risk Karyotpye.

Treatment of Adult T-ALL with a Pediatric Asparaginase-Intensive Protocol Results in Survival Benefit When Compared to Other Adult Based Protocols

Outcome of Patients Age 60 and Over with Acute Lymphoblastic Leukemia (ALL) Treated with a Modified Pediatric Protocol

Pharmacokinetic Results from a Phase 1 Study of a Multi-Targeted Tyrosine Kinase Inhibitor, ABT-869, in Patients with Refractory or Relapsed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only